What is TXG's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 8.51B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TXG?

P/E (TTM) is n/a and 52-week range is $12.80 to $102.81 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TXG figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TXG?

The company profile lists revenue (TTM) near $616M, net income (TTM) near -$6.68B, EPS (TTM) near -$0.52 when available from the market-data feed. Figures are informational and may lag live markets.

Where is 10x Genomics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Pleasanton, California, US, 130.3M shares outstanding, ISIN US88025U1097 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

10x Genomics, Inc.

$TXG

Health Care · Life Sciences Tools & Services

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,178 full-time employees. The company went IPO on 2019-09-12. The firm's integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems. Its products are used across diverse fields, from cancer research and immunology to neuroscience and developmental biology. Its commercial product portfolio is made up of its Single Cell and Spatial solutions. Its products include its instruments, which include its Chromium instruments, its Visium CytAssist and its Xenium Analyzer, and its consumables, which include proprietary microfluidic chips, slides, reagents and other consumables for its Single Cell and Spatial solutions. The company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The company also provides post-warranty service contracts for its instruments.

Employees

1,178

Website

www.10xgenomics.com

IPO

2019-09-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US88025U1097

Headquarters

Pleasanton, California, US

Shares outstanding

130.3M

NAICS sector

Manufacturing

Institutional ownership

111.60%

Browse other companiesFree AI scores and summaries for more stocks